Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Next-gen immuno-oncology therapies in RCC

Ziad Bakouny • 14 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Checkpoint Inhibitors

Ziad Bakouny, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on next-generation immuno-oncology therapies in renal cell carcinoma (RCC). Specifically, he highlights vaccines, new checkpoint inhibitors, and harnessing the metabolomic environment. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Ziad Bakouny

4:31
Cytoreductive nephrectomy for RCC
Ziad Bakouny • 13 Feb 2020
4:49
Potential prognostic markers in sarcomatoid and rhabdoid RCC
Ziad Bakouny • 13 Feb 2020
2:41
Translational approaches in immunotherapy
Ziad Bakouny • 15 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals